Table 1

Univariable and multivariable association between ∆TS and OS, PFS, TDD in HRQoL and PF for patients treated with atezolizumab from OAK and POPLAR

	∆TS (%)	N	Univariable analysis		Multivariable analysis*
	∆TS (%)	N	HR (95% CI)	P value	HR (95% CI)	P value
OS	175 to 30	81	2.40 (1.80 to 3.21)		2.34 (1.72 to 3.18)
	30 to 10	150	1.49 (1.17 to 1.91)		1.48 (1.14 to 1.92)
	10 to −10	300	Reference	<0.001	Reference	<0.001
	−10 to −30	91	0.53 (0.37 to 0.75)		0.48 (0.32 to 0.71)
	−30 to −100	41	0.20 (0.10 to 0.44)		0.22 (0.10 to 0.48)
PFS	175 to 30	81	10.3 (7.70 to 13.8)		10.7 (7.85 to 14.7)
	30 to 10	150	3.84 (3.10 to 4.76)		3.87 (3.07 to 4.89)
	10 to −10	300	Reference	<0.001	Reference	<0.001
	−10 to −30	91	0.49 (0.37 to 0.64)		0.46 (0.34 to 0.61)
	−30 to −100	41	0.33 (0.21 to 0.51)		0.35 (0.22 to 0.56)
TDD in HRQoL	175 to 30	81	1.78 (1.29 to 2.46)		1.71 (1.22 to 2.39)
	30 to 10	149	1.34 (1.04 to 1.72)		1.22 (0.94 to 1.59)
	10 to −10	300	Reference	<0.001	Reference	0.006
	−10 to −30	90	0.97 (0.72 to 1.29)		1.08 (0.79 to 1.47)
	−30 to −100	41	0.54 (0.34 to 0.85)		0.67 (0.41 to 1.08)
TDD in PF	175 to 30	81	1.86 (1.36 to 2.55)		1.72 (1.24 to 2.40)
	30 to 10	149	1.35 (1.04 to 1.74)		1.21 (0.92 to 1.60)
	10 to −10	300	Reference	<0.001	Reference	<0.001
	−10 to −30	90	0.61 (0.43 to 0.86)		0.61 (0.42 to 0.87)
	−30 to −100	41	0.57 (0.36 to 0.92)		0.62 (0.38 to 1.03)

*Multivariable analysis adjusted for baseline ECOG PS, age, sex, race, smoking status, histology, count of prior treatments, PD-L1 expression, serum LDH levels and the presence of liver, lung or brain lesions.
ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, health-related quality-of-life; LDH, lactate dehydrogenase; OS, overall survival; PD-L1, programmed death-ligand 1; PF, physical function; PFS, progression-free survival; TDD, time to deterioration; ∆TS, early changes in tumor size; ∆TS, early changes in tumor size.